Thrombocytopenia caused by the development of antibodies to thrombopoietin.
Thrombocytopenia developed in some individuals treated with a recombinant thrombopoietin (TPO), pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). Three of the subjects who developed severe thrombocytopenia were analyzed in detail to determine the cause of their thrombocytopenia. Except for easy bruising and heavy menses, none of these subjects had major bleeding episodes; none responded to intravenous immunoglobulin or prednisone. Bone marrow examination revealed a marked reduction in megakaryocytes. All 3 thrombocytopenic subjects had antibody to PEG-rHuMGDF that cross-reacted with endogenous TPO and neutralized its biological activity. All anti-TPO antibodies were immunoglobulin G (IgG), with increased amounts of IgG4; no IgM antibodies to TPO were detected at any time. A quantitative assay for IgG antibody to TPO was developed and showed that the antibody concentration varied inversely with the platelet count. Anti-TPO antibody recognized epitopes located in the first 163 amino acids of TPO and prevented TPO from binding to its receptor. In 2 subjects, endogenous TPO levels were elevated, but the TPO circulated as a biologically inactive immune complex with anti-TPO IgG; the endogenous TPO in these complexes had an apparent molecular weight of 95 000, slightly larger than the full-length recombinant TPO. None of the subjects had atypical HLA or platelet antigens, and the TPO cDNA was normal in both that were sequenced. Treatment of one subject with cyclosporine eliminated the antibody and normalized the platelet count. These data demonstrate a new mechanism for thrombocytopenia in which antibody develops to TPO; because endogenous TPO is produced constitutively, thrombocytopenia ensues.
Li
J
J
Hematology Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
Yang
C
C
Xia
Y
Y
Bertino
A
A
Glaspy
J
J
Roberts
M
M
Kuter
D J
DJ
D000328:Adult; D000906:Antibodies / Q000097:blood*; D016572:Cyclosporine / Q000627:therapeutic use; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007700:Kinetics; D008533:Megakaryocytes / Q000473:pathology; D008875:Middle Aged; D008970:Molecular Weight; D009363:Neoplasm Proteins; D010976:Platelet Count; D017713:Platelet Transfusion; D011092:Polyethylene Glycols; D011241:Prednisone / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins / Q000276:immunology*; D013921:Thrombocytopenia / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013926:Thrombopoietin / Q000097:blood / Q000235:genetics / Q000276:immunology*
D000906:Antibodies; D000939:Epitopes; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins; C103117:polyethylene glycol-recombinant human megakaryocyte growth and development factor; C082218:MPL protein, human; D011092:Polyethylene Glycols; D016572:Cyclosporine; D013926:Thrombopoietin; D011241:Prednisone